PMID- 31919804
OWN - NLM
STAT- MEDLINE
DCOM- 20200513
LR  - 20210110
IS  - 1179-1969 (Electronic)
IS  - 1170-229X (Linking)
VI  - 37
IP  - 3
DP  - 2020 Mar
TI  - The Safety and Tolerability of Statin Therapy in Primary Prevention in Older 
      Adults: A Systematic Review and Meta-analysis.
PG  - 175-185
LID - 10.1007/s40266-019-00736-y [doi]
AB  - PURPOSE: The use of statins in the primary prevention of cardiovascular disease 
      (CVD) is increasing in older adults. Nonetheless, good clinical evidence for the 
      safety and tolerability of statins in this population is limited. OBJECTIVE: We 
      aimed to evaluate the safety and tolerability of statins in older adults without 
      overt CVD, focusing on statin-related muscle symptoms. METHODS: Double-blinded 
      randomised controlled trials (RCTs) of statins published before January 2012 were 
      identified from a Cochrane review updated to 2012. Trials published between 
      January 2012 and July 2018 were identified through the CENTRAL, MEDLINE and 
      EMBASE databases. Eligible trials were limited to those including individuals 
      aged >/= 65 years without overt CVD, who were followed for at least 1 year. Trials 
      had to have reported at least one of the outcomes of interest. Pooled relative 
      risk (RR) estimates and 95% confidence intervals (CIs) were calculated using 
      random-effects models. RESULTS: We identified 11 trials, including 18,192 
      participants (mean age 73.7 years; 43% females). Compared with placebo, statins 
      neither increased the risks of muscle-related symptoms (RR 1.01; 95% CI 
      0.90-1.12), total adverse events (AEs) and serious AEs nor led to more total 
      permanent treatment discontinuations and discontinuations due to AEs or 
      specifically due to muscle-related symptoms. No evidence of heterogeneity was 
      observed in any of these outcomes. CONCLUSIONS: This meta-analysis of RCTs found 
      no excess incidence of muscle-related symptoms, total AEs, serious AEs and 
      treatment discontinuations attributable to statin treatment compared with placebo 
      among older adults without CVD.
FAU - Zhou, Zhen
AU  - Zhou Z
AUID- ORCID: 0000-0002-0835-8686
AD  - Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, 
      Australia. zhen.zhou@utas.edu.au.
FAU - Albarqouni, Loai
AU  - Albarqouni L
AD  - The Centre for Research in Evidence-Based Practice (CREBP), Faculty of Health 
      Sciences and Medicine, Bond University, Gold Coast, QLD, Australia.
FAU - Curtis, Andrea J
AU  - Curtis AJ
AD  - Department of Epidemiology and Preventive Medicine, School of Public Health and 
      Preventive Medicine, Monash University, Melbourne, VIC, Australia.
FAU - Breslin, Monique
AU  - Breslin M
AD  - Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, 
      Australia.
FAU - Nelson, Mark
AU  - Nelson M
AD  - Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, 
      Australia.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - New Zealand
TA  - Drugs Aging
JT  - Drugs & aging
JID - 9102074
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
SB  - IM
MH  - Aged
MH  - Cardiovascular Diseases/prevention & control
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*adverse effects/*pharmacology
MH  - Primary Prevention/*methods
MH  - *Safety
EDAT- 2020/01/11 06:00
MHDA- 2020/05/14 06:00
CRDT- 2020/01/11 06:00
PHST- 2020/01/11 06:00 [pubmed]
PHST- 2020/05/14 06:00 [medline]
PHST- 2020/01/11 06:00 [entrez]
AID - 10.1007/s40266-019-00736-y [pii]
AID - 10.1007/s40266-019-00736-y [doi]
PST - ppublish
SO  - Drugs Aging. 2020 Mar;37(3):175-185. doi: 10.1007/s40266-019-00736-y.